Skip to content
Company Analysis

Kiniksa Pharmaceuticals, Ltd. KNSA

A comprehensive view of key metrics, scores, and financial health for Kiniksa Pharmaceuticals, Ltd.

Overview of Kiniksa Pharmaceuticals International, plc

KNSA NMS
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Mid Cap
Kiniksa Pharmaceuticals International, plc (KNSA), is a Mid Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $77.09, about 76.1% overvalued vs fair value, +107.8% 1Y return, placing in the top 25% of its sector.
Metrics P/E 55.2× Rev Growth 60.1% ROE 11.7% Gross Margin 54.7%
USD 77.09
-1.05%
(Delayed)
• Vol 90d: 64.3%
52-Week Range
Market Cap
$4.98B
Enterprise Value
$4.82B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Excellent
Growth
Good
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Excellent
Completeness: 88%
Confidence: 57%
Updated: Sep 12
Top Beats

Quick Facts

Website https://www.kiniksa.com
HQ London
Employees 366
Fiscal year Dec 31

Next Events

Earnings Oct 27 Estimated

Fair Value Snapshot

Bear Base Bull
$17
$18
$20
Current: $77.09 -76% vs base

Engine Room Money Flow™

Mid Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$677.6M
60.1%%
Gross Profit
$370.3M
2.2%%
R&D Expense
$96.9M
-13.2%%
Operating Income (EBIT)
$77.2M
269.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
178.7%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$7.7M
5.7% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
1/2
Improving
1
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Kiniksa Pharmaceuticals, Ltd.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
67
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.92), with robust interest coverage.
  • Consistent Cash Generation Cash generation is strong and consistent (score 0.82).

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.16), suggesting weak customer stickiness.
  • Volatile Margins Suggest Cyclicality Margin volatility is high (stability score 0.19), suggesting cyclical exposure or competitive pressure.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
45
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 94% Coverage
Trade-Off Triangle Visualization A ternary plot showing KNSA's balance between Growth (34.7%), Profitability (29.3%), and Safety (36.1%). Growth 35% Safety 36% Profitability 29%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

77th percentile vs peers
78
Key Signals
Rev Growth YoY 60.1% 92p Revenue CAGR 3Y 45.5% 89p EPS Growth YoY 2.24 90p EPS CAGR 3Y -34.0% 12p
Strengths
  • Rev Growth YoY in top 20% of peers (60.1%, 92th percentile)
  • Revenue CAGR 3Y in top 20% of peers (45.5%, 89th percentile)
  • EPS Growth YoY in top 20% of peers (2.24, 90th percentile)
  • Interest Coverage Ratio in top 20% of peers (7.80, 83th percentile)
Risks

No significant risks identified for this axis.

Profitability

65th percentile vs peers
66
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

80th percentile vs peers
81
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Kiniksa Pharmaceuticals, Ltd..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$18.39
- - -
-76.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000